Bringing you the stock market news that really matters

By using this site you agree to its terms and conditions.  Comments do not represent advice or recommendations to buy or sell any security.


Insider Purchase. September 19th, 2015. Investors may want to follow the lead of insiders at FMC. Priced on a little over 10 times 2016 forecast earnings and down almost 50% from its March 2014 high of $83.94, CEO has bought $2 million of stack and said he does not believe the current share price reflects the prospects of the company. 



Earnings Report November 8th, 2014. IKONICS Reports Record Sales and a 20% Third Quarter Earnings Increase. This was the fourth consecutive quarter of record sales on a quarter-to-quarter comparison basis. Year-to-date earnings are up 69% and sales are up 8% over last year. (article


Potential Value. November 7th, 2014. With people switching to healthier chicken products and increasing general demand for food products, Sanderson Farms has seen sales increasing 10% annually over the past decade (Gurufocus).   Falling input costs should boost earnings further while the completion of a sixth processing plant in 2015 should boost production by 15% (SAarticle).  All this makes the current valuation, with a trailing PE of 10 and forward PE of 8.3, look attractive.


Strong Growth. November 6th, 2014. Archer Daniels Midland almost doubled third quarter EPS to $0.81 from $0.47 and smashed forecasts of $0.73 as corn processing earnings increase $63 million to $171 million and biofuels increased a massive $113 million to $185 million (article).  The company has benefitted from booming biofuels and increasing food demand over the past ten years and believes the outlook for 2015 is bright (article).  Its latest move into flavorings should boost earnings going forward (SAarticle).



Earnings Report November 5th, 2014. Valero Energy Corp reported a jump in third quarter EPS to $2.00 from $0.57 a year ago due to lower crude costs and running at 98% capacity. Operating income more than tripled to $1.67 billion (Article, Press Release). The company did not release guidance but consensus full year (December 2014) EPS forecasts are $5.52 from 16 analysts on revenues of $128.8 billion. Shares of Valero closed up 0.6% at $50.63.

 products include hepatitis C treatment, Olysio, and Invokana for the treatment of type 2 diabetes.